A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours - Concepedia

Concepedia

Publication | Open Access

A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours

DOI Full Paper Access

49

Citations

23

References

2012

Year

Ulrik Lassen, Dorte Nielsen, Morten Mau‐Sørensen, Lena Winstedt, Taina Niskanen, Yvonne Stenberg, Steve Pakola, J M Stassen, S Glazer

British Journal of Cancer

Abstract

TB-403 treatment in this patient population is well tolerated, with a safety profile distinct from that of vascular endothelial growth factor-axis inhibitors.

References

	Year	Citations

Page 1